Assertio (ASRT) Exceeds Q3 Earnings and Revenue Projections
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 10 2025
0mins
Source: NASDAQ.COM
Earnings Performance: Assertio (ASRT) reported quarterly earnings of $0.11 per share, exceeding expectations of a loss of $0.08 per share, marking a significant earnings surprise of +237.50%.
Revenue Growth: The company generated revenues of $49.46 million for the quarter, surpassing the Zacks Consensus Estimate by 83.86% and showing a year-over-year increase from $29.2 million.
Stock Outlook: Assertio shares have declined by 12.7% year-to-date, underperforming the S&P 500, and currently hold a Zacks Rank #3 (Hold), indicating expected performance in line with the market.
Industry Context: The Medical - Drugs industry, to which Assertio belongs, ranks in the top 37% of Zacks industries, suggesting that industry performance could significantly influence Assertio's stock movement in the future.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ASRT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ASRT
Wall Street analysts forecast ASRT stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 23.440
Low
35.00
Averages
40.00
High
45.00
Current: 23.440
Low
35.00
Averages
40.00
High
45.00
About ASRT
Assertio Holdings, Inc. is a pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through the acquisition or licensing of approved products. Its commercial capabilities include marketing through both a sales force and an omni-channel promotion model, market access through payor contracting, and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, and CAMBIA (diclofenac potassium for oral solution). INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID). Otrexup is a once weekly single-dose auto-injector containing methotrexate.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
FTSE Russell Microcap Index Reconstitution Begins
- Sector Rotation: FTSE Russell's preliminary list indicates that companies like Ocugen, Assertio Holdings, Senseonics, CytomX Therapeutics, and iBio are set to join the Russell Microcap Index, reflecting significant shifts within the medical and biotech sectors that could enhance these firms' market visibility and investment appeal.
- Exiting Companies: Companies such as Definium Therapeutics, Tvardi Therapeutics, Rockwell Medical, Quantum-Si, and Capricor Therapeutics are expected to leave the index, which may pressure their stock prices and affect investor confidence, particularly amid intensifying competition in the healthcare sector.
- Effective Date: The reconstitution will officially take effect after US equity markets close on June 26, meaning that the market performance of these companies will be closely monitored, and investors should position themselves ahead of potential market volatility.
- Market Reaction Anticipation: As the healthcare landscape evolves, investors may reassess the valuations of these companies, especially with new entrants likely to drive stock price increases through enhanced liquidity and market recognition.
See More
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
- Legal Investigation Launched: Halper Sadeh LLC is investigating Sila Realty Trust, Inc. (NYSE:SILA) regarding its sale to Blue Owl Real Estate Capital LLC at $30.38 per share, potentially infringing on shareholder rights, aiming to ensure fair treatment for investors.
- UniFirst Shareholder Rights Concern: UniFirst Corporation (NYSE:UNF) is being sold for $155.00 in cash and 0.7720 shares of Cintas stock per share, with Halper Sadeh LLC potentially advocating for higher transaction prices and additional disclosures to protect shareholder interests.
- Assertio Holdings Transaction Review: Assertio Holdings, Inc. (NASDAQ:ASRT) is selling to Garda Therapeutics for $18.00 per share in cash plus a contingent value right, and Halper Sadeh LLC is assessing whether this deal serves the best interests of shareholders, possibly seeking increased compensation.
- Kennedy-Wilson Transaction Risks: Kennedy-Wilson Holdings, Inc. (NYSE:KW) is being sold for $10.90 per share in cash to a consortium led by CEO William McMorrow, with Halper Sadeh LLC potentially representing shareholders to seek better terms and transparency to safeguard their investments.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Insider Trading Investigation: Halper Sadeh LLC is investigating Select Medical Holdings Corporation's sale to a consortium led by its executives and directors for $16.50 per share in cash, which may infringe on shareholder rights.
- UniFirst Acquisition Details: UniFirst Corporation is being sold to Cintas Corporation for $155.00 in cash and 0.7720 shares of Cintas stock per UniFirst share, potentially limiting superior competing offers.
- Centessa Pharmaceuticals Deal: Centessa Pharmaceuticals plc is selling to Eli Lilly for $38.00 in cash per share plus a non-transferable contingent value right that could yield up to $9.00 upon achieving certain milestones, prompting shareholders to consider their rights.
- Assertio Sale Dynamics: Assertio Holdings, Inc. is being sold to Garda Therapeutics for $18.00 per share in cash along with a contingent value right, with Halper Sadeh LLC potentially seeking increased consideration and additional disclosures for shareholders.
See More
Healthcare Stocks Rise 0.8% on NYSE Healthcare Index
- Healthcare Sector Recovery: On Wednesday afternoon, the NYSE Healthcare Index rose by 0.8%, indicating a gradual restoration of investor confidence in the healthcare sector, likely driven by an overall improvement in market sentiment.
- Market Rebound Signs: The increase in healthcare stocks suggests that despite economic uncertainties, investors remain optimistic about the long-term growth potential of the healthcare industry, particularly in areas like drug development and medical technology innovation.
- Increased Investor Attention: As the healthcare sector continues to evolve, heightened investor interest may lead to increased capital inflows into this area, further driving stock prices upward.
- Optimistic Industry Outlook: The growth potential of the healthcare sector is attracting more investor attention, especially against the backdrop of rising global health demands, with expectations for increased investments to support innovation and expansion in the future.
See More
Ademi LLP Investigates Assertio's Transaction Compliance
- Shareholder Rights Investigation: Ademi LLP is investigating Assertio (NASDAQ:ASRT) for potential breaches of fiduciary duty and other legal violations related to its transaction with Zydus, aiming to protect shareholder interests.
- Cash Acquisition Terms: Assertio shareholders will receive $23.50 per share in cash, totaling approximately $166.4 million, reflecting the company's valuation in the merger context.
- Competitive Transaction Restrictions: The transaction agreement imposes significant penalties on Assertio for accepting competing bids, which may undermine the best interests of shareholders by limiting their options.
- Board Responsibility Review: We are examining whether Assertio's board of directors is fulfilling its fiduciary duties to all shareholders, ensuring that their decision-making processes align with the long-term interests of the shareholders.
See More
Assertio and Garda Reach Agreement to Delay Acquisition Launch
- Acquisition Agreement Delay: Assertio and Garda have mutually agreed to postpone the launch of the acquisition tender offer to May 14, 2026, which may affect short-term shareholder decisions and potentially diminish market confidence in the acquisition.
- Cash Acquisition Price: Under the amended merger agreement, Garda will acquire Assertio at $21.80 per share, totaling $153.2 million in cash, a price that may be perceived as insufficiently attractive in the current market environment.
- Convertible Senior Notes Offer Postponed: Assertio has also decided to delay the tender offer for all outstanding Convertible Senior Notes until May 14, 2026, which could influence investors' perceptions of the company's financial stability.
- Future Outlook Uncertainty: The delays in the acquisition and tender offers create uncertainty for Assertio's future development, potentially impacting its competitive position in the oncology market, especially at a critical time when investor attention is heightened.
See More
FTSE Russell Microcap Index Reconstitution Begins
- Sector Rotation: FTSE Russell's preliminary list indicates that companies like Ocugen, Assertio Holdings, Senseonics, CytomX Therapeutics, and iBio are set to join the Russell Microcap Index, reflecting significant shifts within the medical and biotech sectors that could enhance these firms' market visibility and investment appeal.
- Exiting Companies: Companies such as Definium Therapeutics, Tvardi Therapeutics, Rockwell Medical, Quantum-Si, and Capricor Therapeutics are expected to leave the index, which may pressure their stock prices and affect investor confidence, particularly amid intensifying competition in the healthcare sector.
- Effective Date: The reconstitution will officially take effect after US equity markets close on June 26, meaning that the market performance of these companies will be closely monitored, and investors should position themselves ahead of potential market volatility.
- Market Reaction Anticipation: As the healthcare landscape evolves, investors may reassess the valuations of these companies, especially with new entrants likely to drive stock price increases through enhanced liquidity and market recognition.
See More
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
- Legal Investigation Launched: Halper Sadeh LLC is investigating Sila Realty Trust, Inc. (NYSE:SILA) regarding its sale to Blue Owl Real Estate Capital LLC at $30.38 per share, potentially infringing on shareholder rights, aiming to ensure fair treatment for investors.
- UniFirst Shareholder Rights Concern: UniFirst Corporation (NYSE:UNF) is being sold for $155.00 in cash and 0.7720 shares of Cintas stock per share, with Halper Sadeh LLC potentially advocating for higher transaction prices and additional disclosures to protect shareholder interests.
- Assertio Holdings Transaction Review: Assertio Holdings, Inc. (NASDAQ:ASRT) is selling to Garda Therapeutics for $18.00 per share in cash plus a contingent value right, and Halper Sadeh LLC is assessing whether this deal serves the best interests of shareholders, possibly seeking increased compensation.
- Kennedy-Wilson Transaction Risks: Kennedy-Wilson Holdings, Inc. (NYSE:KW) is being sold for $10.90 per share in cash to a consortium led by CEO William McMorrow, with Halper Sadeh LLC potentially representing shareholders to seek better terms and transparency to safeguard their investments.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Insider Trading Investigation: Halper Sadeh LLC is investigating Select Medical Holdings Corporation's sale to a consortium led by its executives and directors for $16.50 per share in cash, which may infringe on shareholder rights.
- UniFirst Acquisition Details: UniFirst Corporation is being sold to Cintas Corporation for $155.00 in cash and 0.7720 shares of Cintas stock per UniFirst share, potentially limiting superior competing offers.
- Centessa Pharmaceuticals Deal: Centessa Pharmaceuticals plc is selling to Eli Lilly for $38.00 in cash per share plus a non-transferable contingent value right that could yield up to $9.00 upon achieving certain milestones, prompting shareholders to consider their rights.
- Assertio Sale Dynamics: Assertio Holdings, Inc. is being sold to Garda Therapeutics for $18.00 per share in cash along with a contingent value right, with Halper Sadeh LLC potentially seeking increased consideration and additional disclosures for shareholders.
See More
Healthcare Stocks Rise 0.8% on NYSE Healthcare Index
- Healthcare Sector Recovery: On Wednesday afternoon, the NYSE Healthcare Index rose by 0.8%, indicating a gradual restoration of investor confidence in the healthcare sector, likely driven by an overall improvement in market sentiment.
- Market Rebound Signs: The increase in healthcare stocks suggests that despite economic uncertainties, investors remain optimistic about the long-term growth potential of the healthcare industry, particularly in areas like drug development and medical technology innovation.
- Increased Investor Attention: As the healthcare sector continues to evolve, heightened investor interest may lead to increased capital inflows into this area, further driving stock prices upward.
- Optimistic Industry Outlook: The growth potential of the healthcare sector is attracting more investor attention, especially against the backdrop of rising global health demands, with expectations for increased investments to support innovation and expansion in the future.
See More
Ademi LLP Investigates Assertio's Transaction Compliance
- Shareholder Rights Investigation: Ademi LLP is investigating Assertio (NASDAQ:ASRT) for potential breaches of fiduciary duty and other legal violations related to its transaction with Zydus, aiming to protect shareholder interests.
- Cash Acquisition Terms: Assertio shareholders will receive $23.50 per share in cash, totaling approximately $166.4 million, reflecting the company's valuation in the merger context.
- Competitive Transaction Restrictions: The transaction agreement imposes significant penalties on Assertio for accepting competing bids, which may undermine the best interests of shareholders by limiting their options.
- Board Responsibility Review: We are examining whether Assertio's board of directors is fulfilling its fiduciary duties to all shareholders, ensuring that their decision-making processes align with the long-term interests of the shareholders.
See More
Assertio and Garda Reach Agreement to Delay Acquisition Launch
- Acquisition Agreement Delay: Assertio and Garda have mutually agreed to postpone the launch of the acquisition tender offer to May 14, 2026, which may affect short-term shareholder decisions and potentially diminish market confidence in the acquisition.
- Cash Acquisition Price: Under the amended merger agreement, Garda will acquire Assertio at $21.80 per share, totaling $153.2 million in cash, a price that may be perceived as insufficiently attractive in the current market environment.
- Convertible Senior Notes Offer Postponed: Assertio has also decided to delay the tender offer for all outstanding Convertible Senior Notes until May 14, 2026, which could influence investors' perceptions of the company's financial stability.
- Future Outlook Uncertainty: The delays in the acquisition and tender offers create uncertainty for Assertio's future development, potentially impacting its competitive position in the oncology market, especially at a critical time when investor attention is heightened.
See More
